Corbus Pharmaceuticals Holdings, Inc.
CRBPHealthcare|Biotechnology|US
$3.07
+0.21 (+7.34%)
DCF Value
$1.97
Tangible Book / Share
$5.27
Cash / Share
$6.08
About
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
Stock Price
-70.6%(1Y)
1M
-41.7%
3M
-69.8%
6M
-72.0%
YTD
-62.3%
1Y
-70.7%
3Y
-19.6%
5Y
-90.6%
Pipeline Summary
11 total trials3
Phase 1
7
Phase 2
3
Phase 3
0
Phase 4
Recruiting: 3Completed: 5Terminated: 3
Active Trials (3)
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
NCT06603844Solid Tumor
Phase 1Phase 2Recruiting
Enrollment: 156 participants
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
NCT07768189Oropharyngeal Carcinoma (OPC)
Phase 3Recruiting
Enrollment: 260 participants
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
NCT06265727Solid Tumor, Adult
Phase 1Phase 2Recruiting
Enrollment: 348 participants
Key Facts
Market Cap$59.4M
Employees36 (+29% YoY)
CEOYuval Cohen
IPO DateOct 27, 2014
Beta2.79
52-Week Range$2.81 – $12.881
Avg Volume831,558
ExchangeNASDAQ
Websitecorbuspharma.com
Ownership
Float72.9%
Shares Outstanding19.3M
Recent Insider Trades
Cormorant Asset Management, LPSELL
Oct 29, 2026425,000 shares @ $4.10
Ben YongSELL
Sep 14, 20262,000 shares @ $7.84
Nicacio Leonardo VianaAWARD
Aug 16, 2026191,676 shares @ $10.09
Nicacio Leonardo VianaAWARD
Aug 16, 202658,333 shares
Saxena Nishant CBUY
Aug 11, 20262,600 shares @ $9.63
Peers
Recent News
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in November
Nov 5, 2026 · globenewswire.com
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock Now Rated “Moderate Buy” by Wall Street Analysts
Oct 25, 2026 · defenseworld.net
Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026
Oct 22, 2026 · globenewswire.com
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
Sep 29, 2026 · globenewswire.com
Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?
Sep 17, 2026 · zacks.com
Data last updated: Nov 9, 2026, 04:04 AM